Search
Displaying 51–60 of 1159 results
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
Foundation News
The gathering will be held June 12–13 and will convene global communities impacted by blinding diseases, alongside researchers, clinicians, patient advocates, and industry partners to foster collaboration, innovation, and hope.
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
The Foundation Fighting Blindness, together with the Nixon Visions Foundation, invites you to join a free, in-person workshop bringing together individuals and families affected by PRPH2 and associated retinal diseases, along with researchers, physicians, and industry partners.
-
Mental Health: Why AI Therapists Can’t Replace Human Connection
WellnessOn their own, digital apps fall short for one reason: the primary catalyst for personal growth and happiness is connection. Not just to a screen or to the words someone is typing, but to a living, breathing person who can empower you to change at the deepest level.
-
Age-Related Macular Degeneration Research Advances
Research NewsRecent developments in research on age-related macular degeneration.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
